{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T21:54:51Z","timestamp":1789941291200,"version":"4.0.1"},"reference-count":79,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100007494","name":"Fondation Plan Alzheimer (Paris)","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007494","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.neuropharm.2017.06.021","type":"journal-article","created":{"date-parts":[[2017,6,22]],"date-time":"2017-06-22T03:16:51Z","timestamp":1498101411000},"page":"446-454","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["Hippocampal 5-HT1A receptor expression changes in prodromal stages of Alzheimer's disease: Beneficial or deleterious?"],"prefix":"10.1016","volume":"123","author":[{"given":"Mathieu","family":"Verdurand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Zimmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2017.06.021_bib1","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0361-9230(01)00614-1","article-title":"Modern views on an ancient chemical: serotonin effects on cell proliferation, maturation, and apoptosis","volume":"56","author":"Azmitia","year":"2001","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.neuropharm.2017.06.021_bib2","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.neuron.2012.03.023","article-title":"Reduction of hippocampal hyperactivity improves cognition in amnestic mild cognitive impairment","volume":"74","author":"Bakker","year":"2012","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2017.06.021_bib3","doi-asserted-by":"crossref","first-page":"26633","DOI":"10.1038\/srep26633","article-title":"Selective serotonin 5-HT1A receptor biased agonists elicitdistinct brain activation patterns: a pharmacoMRI study","volume":"6","author":"Becker","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2017.06.021_bib4","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1111\/cns.12306","article-title":"A\u00a0postmortem study to compare agonist and antagonist 5-HT1A receptor-binding sites in Alzheimer's disease","volume":"20","author":"Becker","year":"2014","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.neuropharm.2017.06.021_bib5","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1056\/NEJM200008173430701","article-title":"Patterns of brain activation in people at risk for Alzheimer's disease","volume":"343","author":"Bookheimer","year":"2000","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.neuropharm.2017.06.021_bib6","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/0166-2236(94)90091-4","article-title":"Neurotransmission\u2013the link integrating Alzheimer research?","volume":"17","author":"Bowen","year":"1994","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.neuropharm.2017.06.021_bib75","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/j.1471-4159.1983.tb11838.x","article-title":"Biochemical assessment of serotonergic and cholinergic dysfunction and cerebral atrophy in Alzheimer's disease","volume":"41","author":"Bowen","year":"1983","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2017.06.021_bib7","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.neuropharm.2008.09.004","article-title":"Region-specific changes in 5-HT1A agonist-induced Extracellular signal-Regulated Kinases 1\/2 phosphorylation in rat brain: a quantitative ELISA study","volume":"56","author":"Buritova","year":"2009","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2017.06.021_bib8","doi-asserted-by":"crossref","first-page":"8740","DOI":"10.1073\/pnas.1206171109","article-title":"Critical role of soluble amyloid-beta for early hippocampal hyperactivity in a mouse model of Alzheimer's disease","volume":"109","author":"Busche","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2017.06.021_bib9","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1126\/science.1162844","article-title":"Clusters of hyperactive neurons near amyloid plaques in a mouse model of Alzheimer's disease","volume":"321","author":"Busche","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2017.06.021_bib10","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0006-8993(97)81700-3","article-title":"WAY 100635, a 5-HT1A receptor antagonist, prevents the impairment of spatial learning caused by intrahippocampal administration of scopolamine or 7-chloro-kynurenic acid","volume":"774","author":"Carli","year":"1997","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2017.06.021_bib11","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1046\/j.1460-9568.1998.00034.x","article-title":"Stimulation of 5-HT1A receptors in the dorsal raphe reverses the impairment of spatial learning caused by intrahippocampal scopolamine in rats","volume":"10","author":"Carli","year":"1998","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2017.06.021_bib12","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1111\/j.1471-4159.1984.tb06081.x","article-title":"Serotonin receptor changes in dementia of the Alzheimer type","volume":"43","author":"Cross","year":"1984","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2017.06.021_bib77","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0197-4580(86)90019-9","article-title":"The selectivity of the reduction of serotonin S2 receptors in Alzheimer-type dementia","volume":"7","author":"Cross","year":"1986","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuropharm.2017.06.021_bib78","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0197-0186(88)90107-6","article-title":"An autoradiographic analysis of serotonin receptors in human temporal cortex: changes in Alzheimer-type dementia","volume":"13","author":"Cross","year":"1988","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.neuropharm.2017.06.021_bib13","doi-asserted-by":"crossref","first-page":"681","DOI":"10.3233\/JAD-2012-121543","article-title":"Episodic-like memory for what-where-which occasion is selectively impaired in the 3xTgAD mouse model of Alzheimer's disease","volume":"33","author":"Davis","year":"2013","journal-title":"J.\u00a0Alzheimers Dis."},{"key":"10.1016\/j.neuropharm.2017.06.021_bib14","doi-asserted-by":"crossref","first-page":"e91203","DOI":"10.1371\/journal.pone.0091203","article-title":"Increased hippocampal excitability in the 3xTgAD mouse model for Alzheimer's disease in\u00a0vivo","volume":"9","author":"Davis","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2017.06.021_bib15","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3389\/fphar.2016.00088","article-title":"Drug development in Alzheimer's disease: the contribution of PET and SPECT","volume":"7","author":"Declercq","year":"2016","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.06.021_bib16","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.jalz.2009.07.003","article-title":"Temporal lobe functional activity and connectivity in young adult APOE varepsilon4 carriers","volume":"6","author":"Dennis","year":"2010","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.neuropharm.2017.06.021_bib17","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/0006-8993(91)90171-Q","article-title":"Autoradiographic analysis of serotonin 5-HT1A receptor binding in the human brain postmortem: effects of age and alcohol","volume":"554","author":"Dillon","year":"1991","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2017.06.021_bib18","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0166-4328(00)00261-8","article-title":"Alzheimer's disease: more than a 'cholinergic disorder' - evidence that cholinergic-monoaminergic interactions contribute to EEG slowing and dementia","volume":"115","author":"Dringenberg","year":"2000","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2017.06.021_bib19","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00401-009-0532-1","article-title":"Classification and basic pathology of Alzheimer disease","volume":"118","author":"Duyckaerts","year":"2009","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.neuropharm.2017.06.021_bib20","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.tins.2011.05.005","article-title":"Neuroimaging markers for the prediction and early diagnosis of Alzheimer's disease dementia","volume":"34","author":"Ewers","year":"2011","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.neuropharm.2017.06.021_bib21","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/6365","article-title":"Learning enhances adult neurogenesis in the hippocampal formation","volume":"2","author":"Gould","year":"1999","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2017.06.021_bib22","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S0169-328X(98)00206-X","article-title":"Cultured astrocytes express messenger RNA for multiple serotonin receptor subtypes, without functional coupling of 5-HT1 receptor subtypes to adenylyl cyclase","volume":"61","author":"Hirst","year":"1998","journal-title":"Brain Res. Mol. Brain Res."},{"key":"10.1016\/j.neuropharm.2017.06.021_bib79","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/0306-4522(90)90246-Z","article-title":"Alzheimer's disease: changes in hippocampal N-methyl-D-aspartate, quisqualate, neurotensin, adenosine, benzodiazepine, serotonin and opioid receptors\u2013an autoradiographic study","volume":"39","author":"Jansen","year":"1990","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2017.06.021_bib23","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1111\/j.1476-5381.2011.01749.x","article-title":"Biased signalling and allosteric machines: new vistas and challenges for drug discovery","volume":"165","author":"Kenakin","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.06.021_bib24","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1073\/pnas.0510237103","article-title":"Serotonin 1A receptors in the living brain of Alzheimer's disease patients","volume":"103","author":"Kepe","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2017.06.021_bib25","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/j.1749-6632.1999.tb07845.x","article-title":"Neurotoxicity and oxidative damage of beta amyloid 1-42 versus beta amyloid 1-40 in the mouse cerebral cortex","volume":"893","author":"Klein","year":"1999","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.neuropharm.2017.06.021_bib26","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1002\/hipo.20022","article-title":"Two reentrant pathways in the hippocampal-entorhinal system","volume":"14","author":"Kloosterman","year":"2004","journal-title":"Hippocampus"},{"key":"10.1016\/j.neuropharm.2017.06.021_bib27","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1038\/npp.2009.207","article-title":"Treatment strategies targeting excess hippocampal activity benefit aged rats with cognitive impairment","volume":"35","author":"Koh","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2017.06.021_bib28","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s00213-010-1936-2","article-title":"Differential involvement of hippocampal serotonin1A receptors and re-uptake sites in non-cognitive behaviors of Alzheimer's disease","volume":"213","author":"Lai","year":"2011","journal-title":"Psychopharmacol. (Berl.)"},{"key":"10.1016\/j.neuropharm.2017.06.021_bib29","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0006-8993(03)02554-X","article-title":"Reduced serotonin 5-HT1A receptor binding in the temporal cortex correlates with aggressive behavior in Alzheimer disease","volume":"974","author":"Lai","year":"2003","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2017.06.021_bib30","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1097\/00001756-200207020-00021","article-title":"Postmortem serotoninergic correlates of cognitive decline in Alzheimer's disease","volume":"13","author":"Lai","year":"2002","journal-title":"Neuroreport"},{"key":"10.1016\/j.neuropharm.2017.06.021_bib31","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3389\/fnagi.2016.00031","article-title":"Implications of GABAergic neurotransmission in Alzheimer's disease","volume":"8","author":"Li","year":"2016","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.neuropharm.2017.06.021_bib32","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.neuropharm.2005.01.007","article-title":"Analysis of the role of 5-HT1A receptors in spatial and aversive learning in the rat","volume":"48","author":"Luttgen","year":"2005","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2017.06.021_bib33","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1124\/mol.106.022756","article-title":"Regional differences in the coupling of 5-hydroxytryptamine-1A receptors to G proteins in the rat brain","volume":"70","author":"Mannoury la Cour","year":"2006","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.06.021_bib34","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1111\/j.1471-4159.1984.tb06098.x","article-title":"Effect of age on human brain serotonin (S-1) binding sites","volume":"43","author":"Marcusson","year":"1984","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2017.06.021_bib35","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3233\/JAD-2010-1220","article-title":"Neuropathologic alterations in mild cognitive impairment: a review","volume":"19","author":"Markesbery","year":"2010","journal-title":"J.\u00a0Alzheimers Dis."},{"key":"10.1016\/j.neuropharm.2017.06.021_bib36","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0893-133X(97)00194-2","article-title":"Serotonin in aging, late-life depression, and Alzheimer's disease: the emerging role of functional imaging","volume":"18","author":"Meltzer","year":"1998","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2017.06.021_bib37","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1124\/jpet.104.069625","article-title":"The serotonin1A receptor partial agonist S15535 [4-(benzodioxan-5-yl)1-(indan-2-yl)piperazine] enhances cholinergic transmission and cognitive function in rodents: a combined neurochemical and behavioral analysis","volume":"311","author":"Millan","year":"2004","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2017.06.021_bib38","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1523\/JNEUROSCI.5215-08.2009","article-title":"Amyloid beta-induced neuronal hyperexcitability triggers progressive epilepsy","volume":"29","author":"Minkeviciene","year":"2009","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2017.06.021_bib39","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/j.1440-1789.2010.01193.x","article-title":"An immunohistochemical study of the serotonin 1A receptor in the hippocampus of subjects with Alzheimer's disease","volume":"31","author":"Mizukami","year":"2011","journal-title":"Neuropathology"},{"key":"10.1016\/j.neuropharm.2017.06.021_bib40","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/0006-8993(92)91100-S","article-title":"Further evidence for differential affinity states of the serotonin1A receptor in rat hippocampus","volume":"590","author":"Mongeau","year":"1992","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2017.06.021_bib41","doi-asserted-by":"crossref","first-page":"a006338","DOI":"10.1101\/cshperspect.a006338","article-title":"Neurotoxicity of amyloid beta-protein: synaptic and network dysfunction","volume":"2","author":"Mucke","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.neuropharm.2017.06.021_bib42","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/j.1476-5381.2008.00001.x","article-title":"Signal transduction and functional selectivity of F15599, a preferential post-synaptic 5-HT1A receptor agonist","volume":"156","author":"Newman-Tancredi","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.06.021_bib43","first-page":"303","article-title":"Neuroreceptor changes in Alzheimer disease","volume":"4","author":"Nordberg","year":"1992","journal-title":"Cerebrovasc. Brain Metab. Rev."},{"key":"10.1016\/j.neuropharm.2017.06.021_bib44","doi-asserted-by":"crossref","first-page":"e210","DOI":"10.1038\/cddis.2011.79","article-title":"Increased hippocampal CA1 density of serotonergic terminals in a triple transgenic mouse model of Alzheimer's disease: an ultrastructural study","volume":"2","author":"Noristani","year":"2011","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.neuropharm.2017.06.021_bib45","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.neurobiolaging.2003.08.012","article-title":"Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease","volume":"24","author":"Oddo","year":"2003","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuropharm.2017.06.021_bib46","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.bbr.2008.02.023","article-title":"The role of 5-HT(1A) receptors in learning and memory","volume":"195","author":"Ogren","year":"2008","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2017.06.021_bib47","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1002\/glia.20967","article-title":"Concomitant astroglial atrophy and astrogliosis in a triple transgenic animal model of Alzheimer's disease","volume":"58","author":"Olabarria","year":"2010","journal-title":"Glia"},{"key":"10.1016\/j.neuropharm.2017.06.021_bib48","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.neuron.2007.07.025","article-title":"Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease","volume":"55","author":"Palop","year":"2007","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2017.06.021_bib49","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1001\/archneurol.2009.15","article-title":"Epilepsy and cognitive impairments in Alzheimer disease","volume":"66","author":"Palop","year":"2009","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.neuropharm.2017.06.021_bib50","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0006-8993(02)03243-2","article-title":"Effects of sex, age, and aggressive traits in man on brain serotonin 5-HT1A receptor binding potential measured by PET using [C-11]WAY-100635","volume":"954","author":"Parsey","year":"2002","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2017.06.021_bib51","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.devbrainres.2005.03.006","article-title":"Ontogeny of 5-HT1A receptor expression in the developing hippocampus","volume":"157","author":"Patel","year":"2005","journal-title":"Brain Res. Dev. Brain Res."},{"key":"10.1016\/j.neuropharm.2017.06.021_bib76","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/0304-3940(84)90402-6","article-title":"Cortical serotonin-S2 receptor binding abnormalities in patients with Alzheimer's disease: comparisons with Parkinson's disease","volume":"51","author":"Perry","year":"1984","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2017.06.021_bib52","doi-asserted-by":"crossref","first-page":"8552","DOI":"10.1523\/JNEUROSCI.19-19-08552.1999","article-title":"Cerebral amyloid induces aberrant axonal sprouting and ectopic terminal formation in amyloid precursor protein transgenic mice","volume":"19","author":"Phinney","year":"1999","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2017.06.021_bib53","doi-asserted-by":"crossref","first-page":"17680","DOI":"10.1523\/JNEUROSCI.4740-11.2011","article-title":"Hippocampal hyperactivation associated with cortical thinning in Alzheimer's disease signature regions in non-demented elderly adults","volume":"31","author":"Putcha","year":"2011","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2017.06.021_bib54","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/ana.22105","article-title":"Hippocampal hyperactivation in presymptomatic familial Alzheimer's disease","volume":"68","author":"Quiroz","year":"2010","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2017.06.021_bib55","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s40265-014-0217-5","article-title":"Serotonergic therapies for cognitive symptoms in Alzheimer's disease: rationale and current status","volume":"74","author":"Ramirez","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.neuropharm.2017.06.021_bib56","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.pneurobio.2012.06.010","article-title":"The serotonergic system in ageing and Alzheimer's disease","volume":"99","author":"Rodriguez","year":"2012","journal-title":"Prog. Neurobiol."},{"issue":"Suppl.\u00a02","key":"10.1016\/j.neuropharm.2017.06.021_bib57","first-page":"116","article-title":"18F-Mefway binding to serotonin 5-HT1A receptors is reduced in transgenic mouse models of Alzheimer's disease","volume":"48","author":"Saigal","year":"2007","journal-title":"J.\u00a0Nucl. Med."},{"key":"10.1016\/j.neuropharm.2017.06.021_bib58","doi-asserted-by":"crossref","first-page":"E2895","DOI":"10.1073\/pnas.1121081109","article-title":"Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model","volume":"109","author":"Sanchez","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2017.06.021_bib59","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1017\/S1461145706007000","article-title":"A\u00a0preliminary open-label study of 5-HT1A partial agonist tandospirone for behavioural and psychological symptoms associated with dementia","volume":"10","author":"Sato","year":"2007","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2017.06.021_bib60","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1124\/jpet.105.086363","article-title":"Lecozotan (SRA-333): a selective serotonin 1A receptor antagonist that enhances the stimulated release of glutamate and acetylcholine in the hippocampus and possesses cognitive-enhancing properties","volume":"314","author":"Schechter","year":"2005","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2017.06.021_bib61","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/153657","article-title":"Effects of S100B on serotonergic plasticity and neuroinflammation in the Hippocampus in down syndrome and Alzheimer's disease: studies in an S100B overexpressing mouse model","volume":"2010","author":"Shapiro","year":"2010","journal-title":"Cardiovasc. Psychiatr. neurol."},{"key":"10.1016\/j.neuropharm.2017.06.021_bib62","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1212\/WNL.0000000000001575","article-title":"The lower hippocampus global connectivity, the higher its local metabolism in Alzheimer disease","volume":"84","author":"Tahmasian","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2017.06.021_bib63","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S0893-133X(00)00227-X","article-title":"Serotonin 5-HT1A receptor binding potential declines with age as measured by [11C]WAY-100635 and PET","volume":"24","author":"Tauscher","year":"2001","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2017.06.021_bib64","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0014-2999(03)01280-9","article-title":"5-HT1A receptor knockout mouse as a genetic model of anxiety","volume":"463","author":"Toth","year":"2003","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.06.021_bib65","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.neuroimage.2008.01.030","article-title":"A\u00a0distinct [18F]MPPF PET profile in amnestic mild cognitive impairment compared to mild Alzheimer's disease","volume":"40","author":"Truchot","year":"2008","journal-title":"Neuroimage"},{"key":"10.1016\/j.neuropharm.2017.06.021_bib66","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1212\/01.wnl.0000271377.52421.4a","article-title":"Up-regulation of hippocampal serotonin metabolism in mild cognitive impairment","volume":"69","author":"Truchot","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2017.06.021_bib67","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jns.2009.08.066","article-title":"A\u00a0serotoninergic basis for hyperphagic eating changes in Alzheimer's disease","volume":"288","author":"Tsang","year":"2010","journal-title":"J.\u00a0Neurol. Sci."},{"key":"10.1016\/j.neuropharm.2017.06.021_bib68","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.neurobiolaging.2009.01.008","article-title":"Effects of amyloid-beta peptides on the serotoninergic 5-HT1A receptors in the rat hippocampus","volume":"32","author":"Verdurand","year":"2011","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuropharm.2017.06.021_bib69","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.neurobiolaging.2015.12.008","article-title":"Differential effects of amyloid-beta 1-40 and 1-42 fibrils on 5-HT1A serotonin receptors in rat brain","volume":"40","author":"Verdurand","year":"2016","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuropharm.2017.06.021_bib70","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.neuropharm.2016.05.009","article-title":"Agonist and antagonist bind differently to 5-HT1A receptors during Alzheimer's disease: a post-mortem study with PET radiopharmaceuticals","volume":"109","author":"Vidal","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2017.06.021_bib71","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.tins.2006.10.002","article-title":"Neurocognitive aging: prior memories hinder new hippocampal encoding","volume":"29","author":"Wilson","year":"2006","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.neuropharm.2017.06.021_bib72","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.molbrainres.2004.07.012","article-title":"Age-dependent effects of serotonin-1A receptor gene deletion in spatial learning abilities in mice","volume":"130","author":"Wolff","year":"2004","journal-title":"Brain Res. Mol. Brain Res."},{"key":"10.1016\/j.neuropharm.2017.06.021_bib73","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/j.neuroimage.2010.03.040","article-title":"High-resolution structural and functional MRI of hippocampal CA3 and dentate gyrus in patients with amnestic Mild Cognitive Impairment","volume":"51","author":"Yassa","year":"2010","journal-title":"Neuroimage"},{"key":"10.1016\/j.neuropharm.2017.06.021_bib74","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s11357-010-9152-x","article-title":"Localization of 5-HT1A and 5-HT2A positive cells in the brainstems of control age-matched and Alzheimer individuals","volume":"32","author":"Yeung","year":"2010","journal-title":"Age (Dordr)"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390817302940?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390817302940?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T18:33:48Z","timestamp":1719254028000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390817302940"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":79,"alternative-id":["S0028390817302940"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2017.06.021","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hippocampal 5-HT1A receptor expression changes in prodromal stages of Alzheimer's disease: Beneficial or deleterious?","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2017.06.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}